If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 292
A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
This study is being done to answer the following question:
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Protocol No
ALLIANCE-A052101
Categories
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Protocol No
AZ-D822GC00001-TRAVERSE
Categories
A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxi
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
Protocol No
AZ-NSABP-D8531C00002-CAMBRIA
Categories
A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-naive or Pre-treated Advanced Dedifferentiated Liposarcoma (Brightline-4)
study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma
Protocol No
BI-1403-0019-BRIGHTLINE-4
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.
Protocol No
BMS-CA0561060
Categories
REACT-AF: Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
REACT-AF Monitoring AFib
Protocol No
CVC-JH-REACT-AF
Categories
An Open-Label, Multi-Center, Single-Arm Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This project is being done to evaluate the safety and tolerability of glofitamab-polatuzumab-R-CHP in patients newly diagnosed DLBCL and determine if a blood test that measures MRD can identify patients most likely to benefit from this regimen.
Protocol No
DFCI-22-606
Categories
A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with FL and who have not received other treatments for their lymphoma
Protocol No
DFCI-22-702
Categories
Brain Alterations in Patients with Cushing's Disease: a Prospective Longitudinal Study
Cushing's Neurocognitive Study
Protocol No
ENDO-IIT-IOACHIMESCU-BACD
Categories
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis
Oral NX-13 in Moderate to Severe Ulcerative Colitis
Protocol No
GI-LANDOS-NX-13-201
Categories